Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All PPI studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPPIsPPIs (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis

Israelsen et al., Clinical Gastroenterology and Hepatology, doi:10.1016/j.cgh.2021.05.011, EUPAS35835
Sep 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality, all patients 5% Improvement Relative Risk Mortality, within cases 12% Ventilation, all patients -8% Ventilation, within cases 0% ICU admission, all patients -5% ICU admission, within c.. 3% Hospitalization, all patients -22% Hospitalization, within c.. -13% Case -8% PPIs for COVID-19  Israelsen et al.  Prophylaxis Is prophylaxis with PPIs beneficial for COVID-19? Retrospective 322,975 patients in Denmark (February - December 2020) Higher hospitalization (p=0.005) and more cases (p=0.0012) c19early.org Israelsen et al., Clinical Gastroenter.., Sep 2021 FavorsPPI Favorscontrol 0 0.5 1 1.5 2+
PPIs for COVID-19
1st treatment shown to increase risk in September 2020
 
*, now with p = 0.00000031 from 37 studies.
* From meta analysis with ≥3 studies.
4,700+ studies for 94 treatments. c19early.org
Retrospective 83,224 SARS-CoV-2 cases and 332,799 controls in Denmark showing increased risk of infection and hospital admission with proton pump inhibitor (PPI) use, but no significant association with ICU admission or mortality.
risk of death, 5.0% lower, RR 0.95, p = 0.70, treatment 166 of 3,955 (4.2%), control 189 of 3,955 (4.8%), NNT 172, adjusted per study, all patients, propensity score matching, multivariable.
risk of death, 12.0% lower, RR 0.88, p = 0.22, treatment 166 of 3,955 (4.2%), control 189 of 3,955 (4.8%), NNT 172, adjusted per study, within cases, propensity score matching, multivariable.
risk of mechanical ventilation, 8.0% higher, RR 1.08, p = 0.73, treatment 55 of 3,955 (1.4%), control 55 of 3,955 (1.4%), adjusted per study, all patients, propensity score matching, multivariable.
risk of mechanical ventilation, no change, RR 1.00, p = 1.00, treatment 55 of 3,955 (1.4%), control 55 of 3,955 (1.4%), adjusted per study, within cases, propensity score matching, multivariable.
risk of ICU admission, 4.8% higher, RR 1.05, p = 0.80, treatment 92 of 3,955 (2.3%), control 95 of 3,955 (2.4%), NNT 1318, adjusted per study, all patients, propensity score matching, multivariable.
risk of ICU admission, 3.0% lower, RR 0.97, p = 0.84, treatment 92 of 3,955 (2.3%), control 95 of 3,955 (2.4%), NNT 1318, adjusted per study, within cases, propensity score matching, multivariable.
risk of hospitalization, 22.0% higher, RR 1.22, p = 0.005, treatment 734 of 3,955 (18.6%), control 650 of 3,955 (16.4%), adjusted per study, all patients, propensity score matching, multivariable.
risk of hospitalization, 13.0% higher, RR 1.13, p = 0.010, treatment 734 of 3,955 (18.6%), control 650 of 3,955 (16.4%), adjusted per study, within cases, propensity score matching, multivariable.
risk of case, 8.0% higher, OR 1.08, p = 0.001, treatment 4,473 of 63,886 (7.0%) cases, 17,553 of 259,089 (6.8%) controls, adjusted per study, case control OR, current vs. non-use, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Israelsen et al., 30 Sep 2021, retrospective, Denmark, peer-reviewed, 7 authors, study period 27 February, 2020 - 1 December, 2020, trial EUPAS35835.
This PaperPPIsAll
Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis
Simone Bastrup Israelsen, Martin Thomsen Ernst, Andreas Lundh, Lene Fogt Lundbo, Håkon Sandholdt, Jesper Hallas, Thomas Benfield
Clinical Gastroenterology and Hepatology, doi:10.1016/j.cgh.2021.05.011
PPI use does not impact SARS-CoV-2 related outcomes No difference -Risk of infection -Severe outcomes
Supplementary Material Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at www.cghjournal.org, and at https://doi.org/10.1016/j.cgh.2021.05.011. Conflicts of interest This author discloses the following: Thomas Benfield reports grants from Novo Nordisk Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Boehringer Ingelheim, grants and personal fees from Gilead, personal fees from MSD, grants from Lundbeck Foundation, grants from Kai Hansen Foundation, and personal fees from Pentabase A/S, with no relation to the work reported in this article. The remaining authors disclose no conflicts. Adjusted for age, sex, comorbidities (peptic ulcer, asthma, chronic obstructive pulmonary disease, cirrhosis, ischemic heart disease, diabetes, renal failure, heart failure, stroke, alcohol-related diagnoses, smoking-related diagnoses, major psychiatric disorders), other current medication use (systemic and inhaled corticosteroids, bronchodilators, H2-receptor antagonists, nonsteroidal anti-inflammatory drugs, anticholinergic agents, immunosuppressants, antipsychotic agents, antibiotics, alcohol abstinence treatment, smoking cessation treatment, blood pressure lowering drugs, lipid lowering drugs, glucose lowering drugs, antiplatelets, anticoagulants), Charlson Comorbidity Index (0, 1-2, 3þ), and number of hospital..
References
Almario, Chey, Spiegel, Increased risk of COVID-19 among users of proton pump inhibitors, Am J Gastroenterol
Benfield, None, Conceptualization: Equal; Funding acquisition: Equal; Investigation: Equal; Methodology: Equal; Supervision: Lead; Writingreview & editing: Equal) Crude Death
Blanc, Waechter, Vogel, Interest of proton pump inhibitors in reducing the occurrence of COVID-19: a casecontrol study, Preprints
Darnell, Subbarao, Feinstone, Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV, J Virol Methods
Elmunzer, Spitzer, Foster, Digestive manifestations in patients hospitalized with COVID-19, Clin Gastroenterol Hepatol
Fan, Liu, Miyata, Effect of acid suppressants on the risk of COVID-19: a propensity score-matched study using UK Biobank, Gastroenterology
Forgacs, Loganayagam, Overprescribing proton pump inhibitors
Gulmez, Holm, Frederiksen, Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study, Arch Intern Med
Herzig, Howell, Ngo, Acid-suppressive medication use and the risk for hospital-acquired pneumonia, JAMA
Huh, Kang, Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea, medRxiv
Kamal, Khan, Sharma, Lack of consistent associations between pharmacologic gastric acid suppression and adverse outcomes in patients with coronavirus disease 2019: meta-analysis of observational studies, Gastroenterology
Kow, Hasan, Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis, J Intern Med
Lambert, Lam, Paik, Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis, PLoS One
Lee, Ha, Yeniova, Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching, Gut
Li, Yu, Do proton pump inhibitors influence SARS-CoV-2 related outcomes? a meta-analysis, Gut
Luxenburger, Sturm, Biever, Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?, J Intern Med
Pottegård, Kristensen, Reilev, Existing data sources in clinical epidemiology: the Danish COVID-19 cohort, Clin Epidemiol
Ramachandran, Perisetti, Gajendran, Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19, Eur J Gastroenterol Hepatol
Tarlow, Gubatan, Khan, Are proton pump inhibitors contributing to SARS-COV-2 infection?, Am J Gastroenterol
Thomsen, Formal analysis: Lead; Investigation: Equal; Methodology: Equal; Writingreview & editing: Supporting) Andreas Lundh (Formal analysis: Supporting; Investigation: Equal; Methodology: Equal; Writingreview & editing: Equal) Lene Fogt Lundbo (Conceptualization: Equal; Investigation: Equal; Methodology: Equal; Writingreview & editing: Equal) Håkon Sandholdt (Formal analysis: Supporting; Investigation: Equal; Methodology: Equal; Writingreview & editing: Supporting) Jesper Hallas (Investigation: Equal; Methodology: Equal; Supervision: Supporting; Writingreview & editing: Equal
Toubasi, Abuanzeh, Khraisat, A meta-analysis: proton pump inhibitors current use and the risk of coronavirus infectious disease 2019 development and its related mortality, Arch Med Res
Ullah, Kocher, Chelala, COVID-19 in patients with hepatobiliary and pancreatic diseases in East London: a singlecentre cohort study, Pancreatology
Vila-Corcoles, Satue-Gracia, Ochoa-Gondar, Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: a population-based cohort study in Southern Catalonia, Spain, J Clin Hypertens
Wiersinga, Rhodes, Cheng, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, JAMA
Xiang, Wong, Hon-Cheong, Exploring drugs and vaccines associated with altered risks and severity of COVID-19: a UK Biobank cohort study of all ATC level-4 drug categories, medRxiv
Xiao, Tang, Zheng, Evidence for gastrointestinal infection of SARS-CoV-2, Gastroenterology
Zhou, Wang, Lee, Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity scorematched territory-wide study, Gut
{ 'indexed': {'date-parts': [[2024, 7, 19]], 'date-time': '2024-07-19T01:37:35Z', 'timestamp': 1721353055286}, 'reference-count': 25, 'publisher': 'Elsevier BV', 'issue': '9', 'license': [ { 'start': { 'date-parts': [[2021, 9, 1]], 'date-time': '2021-09-01T00:00:00Z', 'timestamp': 1630454400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 5, 12]], 'date-time': '2021-05-12T00:00:00Z', 'timestamp': 1620777600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'cghjournal.org', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 9]]}, 'DOI': '10.1016/j.cgh.2021.05.011', 'type': 'journal-article', 'created': {'date-parts': [[2021, 5, 11]], 'date-time': '2021-05-11T17:20:18Z', 'timestamp': 1620753618000}, 'page': '1845-1854.e6', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 28, 'title': 'Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A ' 'Nationwide Study and Meta-analysis', 'prefix': '10.1016', 'volume': '19', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-0653-1289', 'authenticated-orcid': False, 'given': 'Simone Bastrup', 'family': 'Israelsen', 'sequence': 'first', 'affiliation': []}, {'given': 'Martin Thomsen', 'family': 'Ernst', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andreas', 'family': 'Lundh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lene Fogt', 'family': 'Lundbo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Håkon', 'family': 'Sandholdt', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jesper', 'family': 'Hallas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Thomas', 'family': 'Benfield', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.cgh.2021.05.011_bib1', 'doi-asserted-by': 'crossref', 'first-page': '950', 'DOI': '10.1001/archinte.167.9.950', 'article-title': 'Use of proton pump inhibitors and the risk of community-acquired ' 'pneumonia: a population-based case-control study', 'volume': '167', 'author': 'Gulmez', 'year': '2007', 'journal-title': 'Arch Intern Med'}, { 'key': '10.1016/j.cgh.2021.05.011_bib2', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0128004', 'article-title': 'Risk of community-acquired pneumonia with outpatient proton-pump ' 'inhibitor therapy: a systematic review and meta-analysis', 'volume': '10', 'author': 'Lambert', 'year': '2015', 'journal-title': 'PLoS One'}, { 'key': '10.1016/j.cgh.2021.05.011_bib3', 'doi-asserted-by': 'crossref', 'first-page': '2120', 'DOI': '10.1001/jama.2009.722', 'article-title': 'Acid-suppressive medication use and the risk for hospital-acquired ' 'pneumonia', 'volume': '301', 'author': 'Herzig', 'year': '2009', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.cgh.2021.05.011_bib4', 'doi-asserted-by': 'crossref', 'first-page': '85', 'DOI': '10.1016/j.jviromet.2004.06.006', 'article-title': 'Inactivation of the coronavirus that induces severe acute respiratory ' 'syndrome, SARS-CoV', 'volume': '121', 'author': 'Darnell', 'year': '2004', 'journal-title': 'J\xa0Virol Methods'}, { 'key': '10.1016/j.cgh.2021.05.011_bib5', 'doi-asserted-by': 'crossref', 'first-page': '1831', 'DOI': '10.1053/j.gastro.2020.02.055', 'article-title': 'Evidence for gastrointestinal infection of SARS-CoV-2', 'volume': '158', 'author': 'Xiao', 'year': '2020', 'journal-title': 'Gastroenterology'}, { 'key': '10.1016/j.cgh.2021.05.011_bib6', 'doi-asserted-by': 'crossref', 'first-page': '1707', 'DOI': '10.14309/ajg.0000000000000798', 'article-title': 'Increased risk of COVID-19 among users of proton pump inhibitors', 'volume': '115', 'author': 'Almario', 'year': '2020', 'journal-title': 'Am J Gastroenterol'}, { 'key': '10.1016/j.cgh.2021.05.011_bib7', 'article-title': 'Severe clinical outcomes of COVID-19 associated with proton pump ' 'inhibitors: a nationwide cohort study with propensity score matching', 'author': 'Lee', 'year': '2020', 'journal-title': 'Gut'}, { 'key': '10.1016/j.cgh.2021.05.011_bib8', 'article-title': 'Proton pump inhibitor or famotidine use and severe COVID-19 disease: a ' 'propensity score-matched territory-wide study', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Gut'}, { 'key': '10.1016/j.cgh.2021.05.011_bib9', 'article-title': 'Use of proton pump inhibitors and risk of adverse clinical outcomes ' 'from COVID-19: a meta-analysis', 'author': 'Kow', 'year': '2020', 'journal-title': 'J\xa0Intern Med'}, { 'key': '10.1016/j.cgh.2021.05.011_bib10', 'article-title': 'Do proton pump inhibitors influence SARS-CoV-2 related outcomes? a ' 'meta-analysis', 'author': 'Li', 'year': '2020', 'journal-title': 'Gut'}, { 'key': '10.1016/j.cgh.2021.05.011_bib11', 'doi-asserted-by': 'crossref', 'first-page': '875', 'DOI': '10.2147/CLEP.S257519', 'article-title': 'Existing data sources in clinical epidemiology: the Danish COVID-19 ' 'cohort', 'volume': '12', 'author': 'Pottegård', 'year': '2020', 'journal-title': 'Clin Epidemiol'}, { 'key': '10.1016/j.cgh.2021.05.011_bib12', 'doi-asserted-by': 'crossref', 'first-page': 'e15', 'DOI': '10.1016/j.pan.2020.10.005', 'article-title': 'COVID-19 in patients with hepatobiliary and pancreatic diseases in East ' 'London: a single-centre cohort study', 'volume': '20', 'author': 'Ullah', 'year': '2020', 'journal-title': 'Pancreatology'}, { 'key': '10.1016/j.cgh.2021.05.011_bib13', 'doi-asserted-by': 'crossref', 'first-page': '1379', 'DOI': '10.1111/jch.13948', 'article-title': 'Use of distinct anti-hypertensive drugs and risk for COVID-19 among ' 'hypertensive people: a population-based cohort study in Southern ' 'Catalonia, Spain', 'volume': '22', 'author': 'Vila-Corcoles', 'year': '2020', 'journal-title': 'J\xa0Clin Hypertens (Greenwich)'}, { 'key': '10.1016/j.cgh.2021.05.011_bib14', 'doi-asserted-by': 'crossref', 'first-page': '1920', 'DOI': '10.14309/ajg.0000000000000933', 'article-title': 'Are proton pump inhibitors contributing to SARS-COV-2 infection?', 'volume': '115', 'author': 'Tarlow', 'year': '2020', 'journal-title': 'Am J Gastroenterol'}, { 'key': '10.1016/j.cgh.2021.05.011_bib15', 'article-title': 'Association of previous medications with the risk of COVID-19: a ' 'nationwide claims-based study from South Korea', 'author': 'Huh', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.cgh.2021.05.011_bib16', 'article-title': 'Exploring drugs and vaccines associated with altered risks and severity ' 'of COVID-19: a UK Biobank cohort study of all ATC level-4 drug ' 'categories', 'author': 'Xiang', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.cgh.2021.05.011_bib17', 'article-title': 'Interest of proton pump inhibitors in reducing the occurrence of ' 'COVID-19: a case-control study', 'author': 'Blanc', 'year': '2020', 'journal-title': 'Preprints'}, { 'key': '10.1016/j.cgh.2021.05.011_bib18', 'doi-asserted-by': 'crossref', 'first-page': '455', 'DOI': '10.1053/j.gastro.2020.09.028', 'article-title': 'Effect of acid suppressants on the risk of COVID-19: a propensity ' 'score-matched study using UK Biobank', 'volume': '160', 'author': 'Fan', 'year': '2021', 'journal-title': 'Gastroenterology'}, { 'key': '10.1016/j.cgh.2021.05.011_bib19', 'article-title': 'Pre-hospitalization proton pump inhibitor use and clinical outcomes in ' 'COVID-19', 'author': 'Ramachandran', 'year': '2020', 'journal-title': 'Eur J Gastroenterol Hepatol'}, { 'key': '10.1016/j.cgh.2021.05.011_bib20', 'article-title': 'Treatment with proton pump inhibitors increases the risk of secondary ' 'infections and ARDS in hospitalized patients with COVID-19: coincidence ' 'or underestimated risk factor?', 'author': 'Luxenburger', 'year': '2020', 'journal-title': 'J\xa0Intern Med'}, { 'key': '10.1016/j.cgh.2021.05.011_bib21', 'doi-asserted-by': 'crossref', 'DOI': '10.1053/j.gastro.2021.02.028', 'article-title': 'Lack of consistent associations between pharmacologic gastric acid ' 'suppression and adverse outcomes in patients with coronavirus disease ' '2019: meta-analysis of observational studies', 'author': 'Kamal', 'year': '2021', 'journal-title': 'Gastroenterology'}, { 'key': '10.1016/j.cgh.2021.05.011_bib22', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.arcmed.2021.03.004', 'article-title': 'A\xa0meta-analysis: proton pump inhibitors current use and the risk of ' 'coronavirus infectious disease 2019 development and its related ' 'mortality', 'author': 'Toubasi', 'year': '2021', 'journal-title': 'Arch Med Res'}, { 'key': '10.1016/j.cgh.2021.05.011_bib23', 'article-title': 'Digestive manifestations in patients hospitalized with COVID-19', 'author': 'Elmunzer', 'year': '2020', 'journal-title': 'Clin Gastroenterol Hepatol'}, { 'key': '10.1016/j.cgh.2021.05.011_bib24', 'doi-asserted-by': 'crossref', 'first-page': '782', 'DOI': '10.1001/jama.2020.12839', 'article-title': 'Pathophysiology, transmission, diagnosis, and treatment of coronavirus ' 'disease 2019 (COVID-19): a review', 'volume': '324', 'author': 'Wiersinga', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.cgh.2021.05.011_bib25', 'doi-asserted-by': 'crossref', 'first-page': '2', 'DOI': '10.1136/bmj.39406.449456.BE', 'article-title': 'Overprescribing proton pump inhibitors', 'volume': '336', 'author': 'Forgacs', 'year': '2008', 'journal-title': 'BMJ'}], 'container-title': 'Clinical Gastroenterology and Hepatology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1542356521005140?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1542356521005140?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 7, 13]], 'date-time': '2022-07-13T12:48:41Z', 'timestamp': 1657716521000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1542356521005140'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 9]]}, 'references-count': 25, 'journal-issue': {'issue': '9', 'published-print': {'date-parts': [[2021, 9]]}}, 'alternative-id': ['S1542356521005140'], 'URL': 'http://dx.doi.org/10.1016/j.cgh.2021.05.011', 'relation': {}, 'ISSN': ['1542-3565'], 'subject': [], 'container-title-short': 'Clinical Gastroenterology and Hepatology', 'published': {'date-parts': [[2021, 9]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related ' 'Outcomes: A Nationwide Study and Meta-analysis', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Clinical Gastroenterology and Hepatology', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.cgh.2021.05.011', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2021 by the AGA Institute. Published by Elsevier Inc.', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit